Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market Statistics, Development and Growth 2017 to 2023
Summary – A New Market Study, “Global
Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market : Market
Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and
Forecast 2017-2023” Has Been
Featured On Wiseguyreports.
Attention Deficit Hyperactivity Treatment
Disorder
Attention
deficit hyperactivity disorder is one of the most common brain disorder
characterized by impairing and pervasive symptoms of hyperactivity,
inattention, and impulsivity. It is commonly observed in children (<12 years
age) as compared to adolescents. It is also known as hyperkinetic disorder/
attention deficit disorder or neuropsychiatric disorder. The exact cause of the
Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be
resulted due to genetic factors and environmental influences. It results in
improper functioning of the nervous system that led to attention deficit and
hyperactivity/impulsiveness condition. The major symptoms include easy
distraction & striving to maintain focus on one task, unable to remember
things, impatience, and being continuously in motion, among others. The
treatment includes different modalities such as medication, psychotherapy, and
education/training.
The global
Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is growing at
a significant CAGR due to changing in lifestyle and systems impacting the
quality of the births. Increase in the use of preservatives and additives in
children’s diet, an increase in the prevalence of attention deficit
hyperactivity disorder among children about 4–17 year age group expected to
fuel the growth of attention deficit hyperactivity disorder treatment market
over the forecast period. Moreover, increase in the adoption rate of diagnostic
guidelines, increasing awareness among patients and physicians about attention
deficit hyperactivity disorder treatment are expected to bolster the revenue
growth of attention deficit hyperactivity disorder treatment therapeutics
market over the forecast period. However, the presence of comorbid conditions
in children leads to underdiagnoses of attention deficit hyperactivity disorder
treatment, lack of availability of non-stimulant drugs, stringent regulatory
guidelines, and a high cost of the medication are expected to hamper the growth
of attention deficit hyperactivity disorder treatment market over the forecast
period.
The global
Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is segmented
on the basis of medication type, age group, and distribution channel
Based on
medication type, the Attention Deficit Hyperactivity Treatment Disorder (ADHD)
Market has been segmented into following:
Stimulants
Amphetamines
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Non-Stimulants
Atomoxetine
Bupropion
Guanfacine
Based on the
age group, the Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market
has been segmented into following:
Paediatric
Adolescent
Adults
Based on the
distribution channel, the Attention Deficit Hyperactivity Treatment Disorder
(ADHD) Market has been segmented into following:
Hospital
pharmacies
Specialty
clinics
Retail
pharmacies
Online
pharmacies
Nowadays, the
global attention deficit hyperactivity disorder treatment market is in a
nascent stage, several local and international players are actively involved in
the growth of global attention deficit hyperactivity disorder treatment market.
Moreover, several natural alternative remedies are available in the market.
Launching of new products, collaborations, acquisitions and mergers, and
agreements are some of the key strategies followed by various companies to
increase their attention deficit hyperactivity disorder treatment market share.
For instance, in August 2011, MonoSol Rx, was partnered again with KemPharm to
develop a second oral film product to treat attention deficit hyperactivity
disorder treatment. Similarly, in May 2013, NeuroSigma received Health Canada
approval for its Monarch eTNS System for the treatment of the major depressive
disorder and drug-resistant epilepsy, and attention deficit hyperactivity
disorder. Approval for new products from various regulatory bodies such as U.S.
Food and Drug Administration also fuel the growth of the attention deficit
hyperactivity disorder treatment market. For instance, in September 2010,
Actavis receives FDA approval of Atomoxetine HCl Capsules for the treatment of
attention deficit hyperactivity disorder. Entering of generics into the market,
and patent expiries are some key factors drive the attention deficit
hyperactivity disorder treatment market growth over the forecast period.
Globally, the
attention deficit hyperactivity disorder treatment market has been segmented
into the following regions Viz. North America, Europe, Asia-Pacific, Latin
America, and Middle East & Africa. North America holds the largest share in
global attention deficit hyperactivity disorder treatment market followed by
Europe and Asia-Pacific. North America holds the largest share attributed to
rising prevalence of attention deficit hyperactivity disorder, low threshold of
diagnosis is expected to boost the of attention deficit hyperactivity disorder
treatment therapeutics market in North America region over the forecast period.
Moreover, increase in healthcare expenditure, ongoing clinical trials, early
approval of drugs in the U.S., favourable insurance policies for brain
monitoring technologies, and technological advancement for the treatment might
fuel the attention deficit hyperactivity disorder treatment market. Europe
accounts for the significant share attributed to increase in the population,
rising prevalence of attention deficit hyperactivity disorder patients, and increased
in research and development for the innovation of new products. Asia-Pacific
holds a dominant share in attention deficit hyperactivity disorder treatment
market owing to developing healthcare infrastructure, government initiatives, a
rise in population, and an increase in the number of mental disorders. Japan is
the key region in attention deficit hyperactivity disorder treatment market
owing to increase in the prevalence of attention deficit hyperactivity disorder
among children which is approximately 7.7 %.
Some of the
key players in the global attention deficit hyperactivity disorder treatment
market are Neos Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Supernus
Pharmaceuticals, Inc. (U.S.),Shire plc (Ireland), MonoSol Rx(U.S.), KemPharm,
Inc. (U.S.), Neurosigma, Inc. (U.S.) and Actavis (U.S.) to name a few.
In June 2017,
Shire Plc received U.S. FDA approval for a long-acting attention-deficit drug
Adderall XR aimed at adolescents and adults
In December
2015, Pfizer received U.S. Food and Drug Administration approval of Quillichew
ER for attention deficit hyperactivity disorder treatment
Report
Outline:
The report
provides granular level information about the market size, regional market
share and forecast from 2017-2023
The report
covers in-detail insights about the competitor’s overview, key findings and
their key strategies
The report
outlines drivers, restraints, challenges, and trends that are currently faced
by the industry
The report
tracks recent innovations, key developments and startup’s details that are
working in the industry
The report
provides plethora of information about market entry strategies, regulatory
framework and reimbursement scenario
For More Details : https://www.wiseguyreports.com/reports/2753890-global-attention-deficit-hyperactivity-treatment-disorder-adhd-market-market-estimation
About Us:
Wise Guy Reports Is Part Of The Wise Guy Research Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe.
Contact Us:
Norah Trent
Ph: +162-825-80070
(Us)
Ph: +44 2035002763 (Uk)
Comments
Post a Comment